The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


0.5mg milligram(s) Tablet

Novo Nordisk A/SEU/1/00/162/001

Main Information

Active SubstancesRepaglinide
Strength0.5mg milligram(s)
Dosage FormTablet
Licence HolderNovo Nordisk A/S
Licence NumberEU/1/00/162/001

Group Information

ATC CodeA10BX Other blood glucose lowering drugs, excl. insulins
A10BX02 repaglinide


Licence Issued29/01/2001
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back